{
  "id": 8240580,
  "title": "XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity",
  "url": "https://urgent.news/2026/09/18/xortx-announces-planned-fda-ind-submission-for-xrx-026-gout-program",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T12:07:31.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/xortx-announces-planned-fda-ind-submission-for-xrx-026-gout-program-using-xorlo-targeting-usd700m-u-s-gout-market-opportunity"
  },
  "original_language": "en",
  "account": null,
  "summary": "Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026 CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}